Patients with advanced NSCLC, particularly those with adenocarcinomas, are currently tested for the presence of epidermal growth factor receptor (EGFR) mutations, ALK aberrations, and ROS1 aberrations in their tumors because these molecular alterations have therapeutic consequences. The gene discussed is ALK; the disease is non-small cell lung carcinoma.